Grant ID RP220473
Awarded On February 16, 2022
Title Overcoming the CPS1-driven Metabolic Reprogramming and Therapy Resistance in Lethal Prostate Cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Southwestern Medical Center
Principal Investigator/Program Director Ping Mu
Cancer Sites Prostate
Contracted Amount $1,049,997
Lay Summary

The most lethal type of prostate cancer is called metastatic castration resistant prostate cancer, with a 5-year survival rate of only 28%. One of the biggest challenges in managing this disease is that many patients will inevitably develop resistance to the current "standard-of-care" Androgen Receptor (AR) targeted therapies within 2 years. Therefore, there is an overwhelming need to understand the biology of resistance, develop new measurable biological markers to predict resistance, and create a new therapeutic approach to fight against resistance.

We have found, through a technology called "library screening", that the loss of a gene called IWS1, is a key factor leading to therapy resist...

Read More